InvestorsHub Logo
Followers 77
Posts 30218
Boards Moderated 85
Alias Born 03/22/2005

Re: None

Tuesday, 02/21/2023 5:54:02 PM

Tuesday, February 21, 2023 5:54:02 PM

Post# of 447
AbbVie - >>> AbbVie’s top-selling blockbuster drug -- defined as one that generates more than $1 billion in annual sales -- is the rheumatoid arthritis treatment Humira. Although sales from Humira are expected to decline in 2023 when AbbVie's patent for the drug expires, the drugmaker’s portfolio also includes several other products with strong sales performances.

Blood cancer drug Venclexta continues to perform well. The company also expects to profit significantly from its anti-inflammatory drugs Rinvoq and Skyrizi. AbbVie projects combined risk-adjusted sales for the two drugs of $15 billion in 2025.

AbbVie’s pipeline includes 20 different programs in phase 3 testing. Most of the candidates target additional approvals for existing drugs. However, the company is also in the late stages of testing promising new candidate drugs to treat blood cancer, Parkinson’s disease, and wet age-related macular degeneration.

Investors also have a lot to like about AbbVie’s dividend. The company belongs to the elite group of stocks called Dividend Aristocrats that have increased their dividends for at least 25 consecutive years. In just the past five years, AbbVie has increased its dividend by 120%.



Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.